Ketim Therapeutics
Ketim Technologies is a biotech company focused on transforming mental health care through precision medicine. They are developing the world's first objective, blood-based clinical test to predict postpartum depression (PPD) using a proprietary four-protein biomarker signature with up to 94% sensitivity and specificity. Their AI/ML-enabled approach leverages extensive biomarker profiles and clinical data to discover novel therapeutics and create a drug discovery database for PPD. By partnering with hospitals and utilizing biobanks, Ketim aims to address the critical unmet need for early detection and personalized treatment in perinatal mental health, a field currently hampered by a lack of reliable biomarkers and subjective screening methods. Their mission is to diagnose, prevent, predict, and treat psychiatric conditions by translating scientific discoveries into clinical applications, starting with PPD.
Ketim Therapeutics
Ketim Technologies is a biotech company focused on transforming mental health care through precision medicine. They are developing the world's first objective, blood-based clinical test to predict postpartum depression (PPD) using a proprietary four-protein biomarker signature with up to 94% sensitivity and specificity. Their AI/ML-enabled approach leverages extensive biomarker profiles and clinical data to discover novel therapeutics and create a drug discovery database for PPD. By partnering with hospitals and utilizing biobanks, Ketim aims to address the critical unmet need for early detection and personalized treatment in perinatal mental health, a field currently hampered by a lack of reliable biomarkers and subjective screening methods. Their mission is to diagnose, prevent, predict, and treat psychiatric conditions by translating scientific discoveries into clinical applications, starting with PPD.